121804

Żywotność eozynofilii w terapii LAK

•/    W    ■

5

Ifł

Jj

2

i

V.

8

h

Fin •!. ri(cci% of patiem plasm.i and IL-S on coslnophil suiviv.il Purified Humań eosinophil* wcre cultuied with serial dilutions ol plasma from patiem 5 obtalncd on day 5 of IL-2 therapy (Al or dilutions of rhlL-5 os a standard !•). After •» days. eosinophil viabllity was detcrmlned by lluorescein diacetate and propldium lodidc stain-infl. In this assay. 1 U/mL of rblL-S Is «qvnval«nt to8pg- mt